---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-265755"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:25:19.384699+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lexeo reports Q3 2025 net loss $20.3M; FDA open to accelerated BLA for LX2006; raised $154M equity

## Summary
- FDA agreed to consider pooling ongoing Phase I/II LX2006 data with pivotal trial data for BLA; co-primary endpoint earlier than 12 months okayed.
- FDA approved comparability between HEK293 and Sf9 manufacturing processes for LX2006; Sf9 process endorsed for pivotal study.
- LX2006 interim data: 18-23% mean LVMI improvement at 6-12 months in abnormal-baseline patients; 2.0-point mean mFARS improvement (n=16).
- Enrollment complete for LX2020 HEROIC-PKP2 Phase I/II (10 dosed); substantive data update expected January 2026.
- Cash, equivalents, investments $122.8M at Sep 30, 2025; plus $153.8M net from October equity offering funds operations into 2028.

## SEC filing metadata
- accession: 0001193125-25-265755
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000119312525265755/0001193125-25-265755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000119312525265755/lxeo-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-265755
- JSON: https://secwatch.observer/filing/0001193125-25-265755.json
- Plain text: https://secwatch.observer/filing/0001193125-25-265755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.